Monoclonal antibodies in neurology: current state and future development
- Authors: Zakharova M.N.1
-
Affiliations:
- Research Center of Neurology
- Issue: Vol 12, No 5S (2018)
- Pages: 99-104
- Section: Reviews
- URL: https://ogarev-online.ru/2075-5473/article/view/124273
- DOI: https://doi.org/10.25692/ACEN.2018.5.13
- ID: 124273
Cite item
Full Text
Abstract
Monoclonal antibodies are one of the most fastly developing areas of specific therapy for cancer, infectious, autoimmune and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B-lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer's disease, in which monoclonal antibodies are targeted to brain aggregates of beta-amyloid. This review presents new therapeutic approaches to the use of antibody fragments, with a focus of their new class, nanobodies. A special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway.
About the authors
Maria N. Zakharova
Research Center of Neurology
Author for correspondence.
Email: zakharova@neurology.ru
Russian Federation, Moscow
References
- Gajofatto A., Turatti M. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. Expert Opin Invest Drugs 2018; 27(3): 273-286. doi: 10.1080/13543784.2018.1442437. PMID: 29455558.
- Montalban X., Hauser S.L., Kappos L. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209-220. doi: 10.1056/NEJMoa1606468. PMID: 28002688.
- Forsthuber T.G., Cimbora D.M., Ratchford J.N. et al. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 2018; 11: 1756286418761697.doi: 10.1177/1756286418761697. PMID: 29593838.
- Paul F., Murphy O., Pardo S., Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Invest Drugs 2018; 27(3): 265-271. doi: 10.1080/13543784.2018.1443077. PMID: 29465257.
- Arumugakani G., Stephenson S.J., Newton D.J. et al. Early emergence of CD19-negative human antibody-secreting cells at the plasmablast to plasma cell transition. J Immunol 2017; 198(12): 4618-4628. doi: 10.4049/jimmunol.1501761. PMID: 28490574.
- van Dyck C.H. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry 2017; 83(4): 311-319. doi: 10.1016/j.biopsych.2017.08.010. PMID: 28967385
- Hamers-Casterman C., Atarhouch T., Muyldermans S. et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363(6428): 446-448. doi: 10.1038/363446a0. PMID: 8502296.
- Rissiek B., Koch-Nolte F., Magnus T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Сell Neurosci 2014; 8:344. doi: 10.3389/fncel.2014.00344. PMID: 25374510.
- Peyvandi F., Scully M., Kremer Hovinga J.A. et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2017;15(7): 1448-1452. doi: 10.1111/jth.13716. PMID: 28445600
- Butler D.C., Joshi S.N., De Genst E. et al. Bifunctional anti-non-amyloid component α-Synuclein nanobodies are protective in situ. PloS One 2016; 11(11): e0165964. doi: 10.1371/journal.pone.0165964. PMID: 27824888.
- Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem 2013; 82: 775-797. doi: 10.1146/annurev-biochem-063011-092449.PMID: 23495938.
Supplementary files
